AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 101 min read$INSM

Lewis William sold $613K of INSM

Lewis William (Chair and CEO) sold 6,515 shares of INSMED Inc (INSM) at $94.03 ($0.61M total) on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lewis William
Published Jun 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INSM
Neutral
medium confidence
Mentioned
$INSM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The newest fact is the CEO/Chair’s open-market sale amount and execution date (June 8) under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment/positioning, but the 10b5-1 structure limits fundamental read-through.

03

What to watch

The filing does not indicate whether other insiders/large holders are buying, nor does it provide context on total insider ownership changes beyond the post-transaction balance.

Relevance 4/10Novelty 5/10Timing: Filed June 10; sale executed June 8.

Background

The article is an SEC Form 4 insider transaction disclosure for INSMED Inc.

Company-level read

Ticker impact

$INSMNeutralMedium confidence
Context

INSMED CEO/Chair Lewis William filed an open-market sale of 6,515 shares (~$612.6K) under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and quickly absorbed.

Evidence & confidence

The disclosure is a Form 4 insider sale (not a buy) and is explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Minimal; single-company insider transaction without accompanying operational/regulatory/clinical catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

10b5-1 sales can be purely mechanical; the market may overreact to the headline “insider selling” despite no new company-specific information.

Key entities

  • issuer
    INSMED Inc

    Company whose shares were sold by an insider (Lewis William).

  • insider
    Lewis William

    Chair and CEO who sold 6,515 shares on June 8, 2026 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INSM insider trading history →

Related articles

SEP 28
$INSMMedAI 8/10

Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?

Insmed (INSM) announced the FDA granted priority review for its ARIKAYCE lung drug, setting a January 2027 decision date. The application seeks full approval for broader use in treating MAC lung disease. Clinical trial results showed significant improvements in respiratory symptoms and bacterial conversion rates. Success could expand the patient pool and increase revenue, but regulatory, tolerability, and commercialization risks remain.

insidermonkey.com2 min
SEP 22
$INSMHighAI 8/10

FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce

Insmed (INSM) announced the FDA accepted its filing for Arikayce's label expansion to treat newly diagnosed MAC lung disease, with a decision expected by Jan. 28, 2027. The filing is supported by positive phase IIIb ENCORE study results. Arikayce sales grew 7% YoY to $214.4M in H1 2026, with full-year sales projected at $450M-$470M. The expansion could significantly increase Arikayce's market potential, according to the company.

zacks.com2 min
SEP 21
HighAI 8/10

Why is Insmed stock climbing today?

Insmed stock rose 2.0% in pre-market trading after the FDA accepted and granted Priority Review to its sNDA for ARIKAYCE, targeting a decision by January 28, 2027. The application seeks full approval for the drug, backed by Phase 3b ENCORE study results. Full approval would expand ARIKAYCE's use to newly diagnosed patients and those with recurrent infections. Insmed also plans to engage Japan's pharmaceutical regulator in Q4 2026 for potential label expansion.

investing.com2 min
SEP 21
$INSMHighAI 8/10

Insmed stock rises on FDA priority review for Arikayce

Insmed Inc. (NASDAQ:INSM) shares rose 2% premarket after the FDA granted priority review to its sNDA for Arikayce, targeting MAC lung disease. The FDA set a review deadline of January 28, 2027. Arikayce, approved in 2018, could see expanded use if the application succeeds. The sNDA is backed by Phase 3b ENCORE study results showing significant improvements in respiratory symptoms and culture conversion.

investing.com1 min